AI Insight
A large real-world study found that semaglutide, the active ingredient in Ozempic and Wegovy, was associated with approximately 40% fewer asthma attacks and 20% fewer COPD exacerbations in patients using these medications. The findings suggest that GLP-1 receptor agonist drugs may provide respiratory benefits beyond their established effects on diabetes and weight management. Researchers emphasize that controlled clinical trials are necessary to confirm these observational associations.
Why it matters
If confirmed through clinical trials, these findings could expand treatment options for millions of people suffering from asthma and COPD, two of the most common chronic respiratory conditions worldwide. The potential dual benefit of managing metabolic conditions while simultaneously reducing respiratory symptoms could represent a significant advancement in patient care.
Understand the Science
Semaglutide, the drug found in Ozempic and Wegovy, was linked to nearly 40% fewer asthma attacks in a large real-world study. It was also associated with about 20% fewer COPD flare-ups. Researchers say GLP-1 drugs may offer respiratory benefits in addition to their effects on diabetes and obesity, but clinical trials are needed to confirm the findings.
Source: Ozempic and Wegovy linked to nearly 40% fewer asthma attacks